äºé²å»åŠãå¥åº·èšºæãçæŽ»ç¿æ £æ¹åã«é¢ããæ å ±äº€æ
43
ã¡ã³ããŒ
33
æçš¿
å®å®¶ã®èŠªãé«è¡å§ãšèšãããŠãèªåãé£ç掻ãèãããã£ããã«ãªããŸããããšããããå³åæ±ã®å¡©åãæžãããŠãå€é£ã®ãšãã¯éººé¡ã®ã¹ãŒããæ®ãããã«ããŠããŸããå°å³ã§ããäºã¶æãããã§å°ãäœã軜ããªã£ãæ°ãããŸããå®¶æã®ç æ°ããã£ããã«ç掻ãå€ããæ¹ãããŸããã
掟æãªæ°æè¡ã®è©±ãæ°ã«ãªããŸãããèªåã¿ãããªæ®éã®äººéããŸãããã¹ãããšã£ãŠãç¡ç ã»éåã»é£äºã®åºæ¬ãªã®ããªãšæè¿ãããããŠæã£ãŠããŸãã ã¿ãªãããç¶ããŠããç¿æ £ã§ãããã¯å¹æãæãããšãããã®ãããã°å ±æããŠã»ããã§ãããããŸã§äœæã¬ãã«ã®è©±ã§æ§ããŸããã
èåãã现èãè¥ãç¶æ ã«æ»ãââSFã®ãããªçºæ³ããã€ãã«äººã®äœã§è©ŠãããŸããã ãäœãèµ·ããã®ãã ç±³Life Biosciencesãã现èãªããã°ã©ãã³ã°æè¡ã䜿ã£ãäžçåã®äººäœèšåºè©Šéšã«ã€ããŠãFDAïŒç±³é£åå»è¬åå±ïŒããæ²»éšéå§ã®æ¿èªïŒIND clearanceïŒãååŸããŸããã察象ã¯éæŸé è§ç·å éãNAIONïŒéåèçæ§åéšèè¡æ§èŠç¥çµçïŒãªã©å 霢ã«äŒŽãèŠç¥çµã®ç æ°ã§ãè¬å€ãER-100ããçšããŸããæ£è ã®çµã¿å ¥ãã¯ããããå§ãŸã段éã§ãå®éã®æäžçµæã¯ãŸã å ±åãããŠããŸããã ããªããã°ã©ãã³ã°ãšã¯ã 京éœå€§åŠã®å±±äžäŒžåŒ¥ææãèŠã€ãããå±±äž4å åãã¯ãæçãã现èãåæç¶æ ã«æ»ãéºäŒåã®ã»ããã§ããä»åã¯ãã®ãã¡3å åïŒOSKïŒã ãã䜿ãã现èãå®å šã«åæåãããè¥ãé ã®åãã«è¿ã¥ãããéšåçãªããã°ã©ãã³ã°ããçããŸããåç©å®éšã§ã¯èŠç¥çµã®æ©èœå埩ãå ±åãããŠããŸããã ããªã泚ç®ãã ãããŸã§èåç ç©¶ã®å€ãã¯å¹é€çްèãåç©ã®æ®µéã§ãããä»åã¯ããã®ä»çµã¿ãäººã§æ€èšŒããéãåããŠå ¬åŒã«éãããäžæ©ã§ããå®å šæ§ãšå¹æã¯ããããå§ãŸã詊éšã§ç¢ºãããããŸãã åºå žïŒLifespan.ioïŒ2026幎2æ6æ¥ïŒ æ¬èšäºã¯æ å ±æäŸãç®çãšãããã®ã§ã蚺æãæ²»çæ¹éã¯å¿ ã䞻治å»ã«çžè«ããŠãã ããã

First Human Cellular Reprogramming Trial Cleared by the FDA
Life Biosciences' trial of cellular reprogramming aimed at age-related vision diseases has received a go-ahead from the FDA. We spoke with the companyâs CSO.
lifespan.io
ããæè¿ã现èãè¥è¿ããããšãèåãå·»ãæ»ãã¿ãããªè©±é¡ãããç®ã«ããŸããæ£çŽããããããäžæ¹ã§ãã©ããŸã§ãæ¬åœã«äººã§å¹ãã®ãããŸã åç©ã®æ®µéãªã®ããåºå¥ãã€ããªããªã£ãŠããŸããã 詳ããæ¹ã«èãããã®ã§ããããããããªããã°ã©ãã³ã°ç³»ã®è©±ã£ãŠãä»ã¯ãå®å šæ§ã確ãããå ¥å£ããããã®çè§£ã§åã£ãŠããŸãã?éåºŠã«æåŸ ããããªãããã«ãããã®ã§ãçŸå®çãªè·é¢æãç¥ãããã§ãã
èŠç¥çµã®ç ç©¶ãèåç ç©¶ã®å ¥å£ã«ãªã£ãŠããããšãã話ãèªãã§æ°ã«ãªããŸããã ç®ã¯å€ããæ€æ»ããããããç ç©¶ã®å¯Ÿè±¡ã«ãªããããããšããäºæ ã¯äœãšãªããããã®ã§ãããç®ã§èµ·ããŠããããšãšäœå šäœã®èåã£ãŠãã©ã®ãããã€ãªãã£ãŠãããã®ãªãã§ãããããããŸã§çŽ æŽãªçåã§ãã
éºäŒåã®æ€æ»ã§ç æ°ã®ãªã¹ã¯ãæ©ãåããæä»£ã«ãªã£ãŠããŸããããããçºçåã«åãã£ãå ŽåãçæŽ»ç¿æ £ã§ã§ããããšã£ãŠã©ã®ããããããã§ãããã ãã¡ããç æ°ã«ãã£ãŠéããšã¯æããŸãããã ãæ²»çæ³ãåºãŠãããŸã§ã®éãé£äºãå®ææ€æ»ã§é²è¡ãé ããããããã®ããããšèããŠãååãã«èããããããããªãšæã£ãŠããŸãã
芪æã«éºäŒæ§ã®çŸæ£ããã人ãããŠãèªåã«ãé¢ä¿ããã®ãæ°ã«ãªã£ãŠå°ããã€èª¿ã¹ãŠããŸããæ€æ»ãäºé²ã®éžæè¢ã«ã€ããŠæ å ±ã¯å¢ããŠãããã®ã®ãã©ãããæãã€ããã°ãããè¿·ãããšãå€ãã§ããåãç«å Žã§æ å ±åéããŠããæ¹ãããããã©ããªé çªã§èª¿ã¹ããèããŠã¿ããã§ãã
æ¯å¹Žå¥åº·èšºæãåããŠããŸãããçµæãããã£ãŠããåºæºå€å ãã©ããããšãå»å¹Žãšæ¯ã¹ãŠã©ããããããããèŠãããŠããŸããã æ¬åœã¯é ç®å士ã®é¢ä¿ããæ°å¹Žåäœã®åŸåã§èªãã»ããæå³ããããšèããããšããããŸããå°éç¥èããªããŠãèªåã§ã§ããç¯å²ã§ãããå°ãèžã¿èŸŒãã èŠæ¹ãããã°æããŠã»ããã§ãã
å®å®¶ã®èŠªãæè¿äœèª¿ã厩ããã¡ã§ããã£ãšæ©ãããçæŽ»ç¿æ £ã«æ°ãã€ããŠããã°ãšããè©±ãæ¬äººãšãããŠããŸãã èªåãååãéããŠãä»ããã§ãã§ããäºé²ã£ãŠäœã ãããšèããããã«ãªããŸãããæŽŸæãªããšã§ã¯ãªããç¶ããããå°ããªç¿æ £ã®ã»ããçµå±å¹ãã®ããªãšæè¿ã¯æã£ãŠããŸããåããããªå¹Žä»£ã®æ¹ã®äœéšè«ãèããŠã¿ããã§ãã
ãã®ã³ãã¥ããã£ãããèŠãŠããã®ã§ãããéºäŒåæ²»çã®è©±é¡ãšäºé²å»çã£ãŠä»åŸã€ãªãã£ãŠãããã§ããããã çºäœãæãããçç¶ãæãããšããæ²»çã®è©±ãå€ãå°è±¡ã§ããããããçºçåã®ãªã¹ã¯æ®µéã«ä»å ¥ããæ¹åã«ãåºããã®ããçŽ äººã®çŽ æŽãªçåã§ãã詳ããæ¹ã®èŠç«ãŠãèããŠã¿ããã§ãã
æ¯å¹Žã®å¥åº·èšºæã§LDLã³ã¬ã¹ãããŒã«ãåºæºå€ãå°ãè¶ ããŠããŠããã£ãšæ§åèŠãšèšãããŠããŸããåçå»çãæ°è¬ã®ãã¥ãŒã¹ã远ã£ãŠãããšãçµå±ã®ãšããæ¥ã ã®äºé²ãäžçªå°å³ã ãã©å€§äºãªãã ãªãšæããŸãã é£äºãšéå以å€ã§ãçãããç¶ããŠããäºé²ç¿æ £ãããã°åèã«ãããã§ãã
ä»å¹Žã®å¥åº·èšºæã§LDLã³ã¬ã¹ãããŒã«ãããé«ããšåºãŸãããããè¬ãšããæ°å€ã§ã¯ãªããããããŸãã¯é£äºãšéåã§æ§åãèŠãŸããããšèšãããŠããŸãã æã®ãŠã©ãŒãã³ã°ãå§ããŠäºãæãæãç©ãæžãããŠééãå¢ãããŸãããæ¬¡ã®æ€æ»ã§ã©ãå€ããããå忥œãã¿ã§ååäžå®ã§ããåãããã«ç掻æ¹åã§æ°å€ãåããæ¹ã®è©±ãèããŠã¿ããã§ãã
éºäŒåãåå ã®ç æ°ã®è©±ãèªãã§ãããšãäºé²ãšããèšèã®æå³ãå°ãå€ãã£ãŠããæ°ãããŸããçæŽ»ç¿æ £ã§é²ãäºé²ãšãéºäŒçãªãªã¹ã¯ãžã®åãåãæ¹ã¯å¥ç©ã§ãããã å®¶ææŽããã人ã«ãšã£ãŠã¯ãæ©ãã«ç¥ã£ãŠããããšãã®ãã®ãäžã€ã®åãã«ãªãã®ããªãšæããŸãããé£ããããŒãã§ãããããããè°è«ãã§ããå Žãããã®ã¯ãããããã§ãã
äºé²ã®èгç¹ã§åžè²©ã®éºäŒåæ€æ»ããããæ°ã«ãªã£ãŠããŸãã äœè³ªãçŸæ£ãªã¹ã¯ãåãããšããè§Šã蟌ã¿ã§ããã粟床ã䜿ãã©ãããæ£çŽããåãããŸãããå®éã«äœ¿ã£ãŠã¿ãŠã©ãã ã£ãããææ³ãèãããšå¬ããã§ãã
æ¯å¹ŽLDLãå°ããã€äžãã£ãŠããŠã忀æ»ã§ã¯ãªãããã©çµé芳å¯ãšèšãããŸããã é£äºãšéåã§æ§åãèŠãŠããã®ã§ãããæ°å€ã®äžäžã«äžåäžæããŠããŸããŸãã çæŽ»ç¿æ £ã®æ¹åã£ãŠã©ã®ãããã®æéã§çµæãèŠãããã®ãªãã§ãããããæ°é·ã«ãããããªããšã¯æãã€ã€ã
éºäŒãé¢ããç æ°ã®ãã¥ãŒã¹ãèªããã³ã«ãèªåãå®¶æã¯ã©ããªãã ãããšæ°ã«ãªããŸãããšã¯ãã調ã¹ãŠäœãåãã£ããšããåãæ¢ããããããšããäžå®ããã£ãŠã åãããã«è¿·ã£ãããšã®ããæ¹ãããŸãããæ€æ»ãåããã»åããªãã£ããããããã©ããªæ°æã¡ã ã£ãããããå·®ãæ¯ããªããã°èããŠã¿ããã§ãã
å æ¥ãå®å®¶ã®æ¯ã®å¥åº·èšºæã®çµæãäžç·ã«èŠãæ©äŒããããŸããã èªåãäŒç€Ÿã§åããŠãããã®ãšæ¯ã¹ããšãé ç®ã®çްãããå šç¶éããã§ãããæ¯ã®æä»£ã¯ããšããããäžéãããšããæãã ã£ãã®ããä»ã¯çæŽ»ç¿æ £ã«åãããŠéžã¹ãæ€æ»ãå¢ããŠããå°è±¡ã§ãã éžæè¢ãå¢ããã¶ããäœãåããã°ããã®ãè¿·ãã®ãäºå®ã§ãã¿ãªããã¯æ€èšºã®é ç®ãã©ãããåºæºã§éžãã§ããŸãããå®¶æã®è©±ãå«ããŠèããŠã¿ããã§ãã
ãäžçåã®ãªããã°ã©ãã³ã°èšåºè©Šéšãå§åã Life Biosciences瀟ãéçºãããER-100ãããäžçã§åããŠéšåçãªããã°ã©ãã³ã°(现èã®è¥è¿ã)ã人äœã«è©Šãèšåºè©Šéšãžã®æ£è ç»é²ãéå§ããŸããã察象ã¯å€±æã«ã€ãªããèŠç¥çµçŸæ£ãLHON(ã¬ãŒããŒéºäŒæ§èŠç¥çµç)ãã®æ£è ã§ãã ãER-100ãšã¯ã å±±äžäŒžåŒ¥ææãiPS现èã®äœè£œã§çšãããå±±äžå åãã®ãã¡3ã€(OCT4ã»SOX2ã»KLF4)ãçŒã«å±ããå·ã€ããç¶²èç¥çµç¯çްèãè¥ãç¶æ ã«ãªã»ããããããšãç®æãéºäŒåæ²»çã§ããåç©å®éšã§ã¯ããŠã¹ããµã«ã®èŠåãå埩ãããšå ±åãããŠããŸãã ããªãç»æçãã ãããŸã§èåã现èã¬ãã«ã§å·»ãæ»ãã¢ãããŒãã¯åºç€ç ç©¶ã«çãŸã£ãŠããŸãããä»åã¯FDAãIND(æ²»éšéå§ç³è«)ãæ¿èªããããã§å®å šæ§ãšå¹æã確ãããæ®µéã«å ¥ããŸããèŠç¥çµãšãããéããçµç¹ãããå§ããã®ã¯ããªã¹ã¯ãéå®ããããã®æ éãªèšèšã§ãã ãæåŸ ãšæ³šæç¹ã æåããã°ãç·å éãªã©ä»ã®èŠç¥çµçŸæ£ãããã«ã¯ä»ã®èåšã®èåé¢é£çŸæ£ãžã®å¿çšãèŠéã«å ¥ããŸãããã ãèšåºè©Šéšã¯å§ãŸã£ãã°ããã§ãæå¹æ§ãå®å šæ§ã確ç«ãããããã§ã¯ãããŸãããåæããŒã¿ã®å ¬éã«ã¯æ°å¹ŽãããèŠèŸŒã¿ã§ãã åºå ž:MIT Technology ReviewãLife Bioscienceså ¬åŒçºè¡š â»æ¬èšäºã¯æ å ±æäŸãç®çãšãããã®ã§ã蚺æãæ²»çæ¹éã¯å¿ ã䞻治å»ã«çžè«ããŠãã ããã

The first human test of a rejuvenation method will begin âshortlyâÂ
In a bid to treat blindness, Life Biosciences will try out potent cellular reprogramming technology on volunteers.
www.technologyreview.com
äºé²å»åŠã«èå³ããã£ãŠãã¿ãã³Dã話é¡ã«ããåºãŠããã®ã§ããã è¡æ¶²æ€æ»ã§æ°å€ã確èªããŠããè£å ããã®ãåºæ¬ã ãšãã話ãèããŸããã äžæ¹ã§ãæ¥æ¬äººã¯å šäœçã«äžè¶³ããã¡ãªã®ã§è»œãéãªãæ€æ»ãªãã§ãããããšããæèŠããã£ãŠæ··ä¹±ããŠããŸãã å®éã«ãã¿ãã³Dè£å ãåãå ¥ããŠããæ¹ãæ€æ»ã¯ãããŸããã? ã©ã®ãããã®éã§å§ããŸããã? (ããã¯å人ã®äœéšè«ãåéããæçš¿ã§ãå»åŠçã¢ããã€ã¹ãæ±ããŠããããã§ã¯ãªãã§ããæçµå€æã¯å»åž«ã«çžè«ããŸãã)
æ¯æ¹ã®ç¥æ¯ãšæ¯ãäž¡æ¹ãšãã¢ã«ããã€ããŒåãšèšºæãããŠãèªåã40代åŸåã«å ¥ã£ãã®ã§ãæ¬æ°ã§äºé²ãèããŠããŸãã Lancetã®ãä¿®æ£å¯èœãª12ã®ãªã¹ã¯å åãã¯äžéãèªã¿ãŸããããå ·äœçã«äœããæãã€ãããåªå é äœãã€ãã«ããã§ãã éåã»ç¡ç ã»èŽèŠã±ã¢ã»ç³å°¿ç 管çããããäžäœã§ãããçãããå®¶ææŽããã§å®éã«ãã£ãŠãã察çãããã°æããŠãã ããããµããªç³»ã®è©±ã¯ååã«æççã«èªãã§ããã®ã§ãçæŽ»ç¿æ £ããŒã¹ã®å®äœéšãèãããã§ãã
ç¶ã60代ã§å¿çæ¢å¡ãèµ·ãããŠãããèªåã®åè硬åãªã¹ã¯ãæ°ã«ãªã£ãŠããŸãã LDLã³ã¬ã¹ãããŒã«ã¯å¥èšºã§åºãã®ã§ãããLp(a)ã¯å¥ãªãã·ã§ã³ã«ãªãããšãå€ããšèããŸãããäžçã«äžåºŠæž¬ãã°ãããéºäŒã§æ±ºãŸãé ç®ã ããšãããšãããŸã§ã¯èª¿ã¹ãã®ã§ãããå®éã«ãªãã·ã§ã³ã§ã€ããããšã®ããæ¹ãã³ã¹ãã®ç®å®ããçµæã䞻治å»ã«ã©ã掻ãããŠããã£ããæããŠããããªãã§ããããã
䞡芪ãšå åŒã®ã³ã¬ã¹ãããŒã«å€ãèããŠåã£ãŠãå®¶ç³»å³ã«æžãåºããŠã¿ãããç¶æ¹ã®ç¥ç¶ã»ç¶ã»åæ¯ã»èªåãå šå¡LDLãåºæºå€ã®åè¿ããã£ãŠããããå šå¡30代ããå¿è¡ç®¡ç³»ã®ã€ãã³ããããããšããã®ã«æ°ã¥ããŸããã å»åž«ã«çžè«ãããå®¶ææ§é«ã³ã¬ã¹ãããŒã«è¡ç(FH)ã®çãã匷ããšããããšã§ãéºäŒåŠçæ€æ»ã𿩿ããã®ã¹ã¿ãã³å°å ¥ã®è©±ã«ãªããŸããã æžããŠã¿ããŸã§ããã ããã¡ã¯è¡ãæ¿ãããããããã«æã£ãŠããã®ã§ãããçŽã«æžããšäžæ°ã«åãå€ãããŸããåãããã«å®¶æã®æ°å€ãæ°ã«ãªã£ãŠããæ¹ãäžåºŠå®¶ç³»å³ã«ããŠã¿ãããšãããããããŸãã
æ°å¹Žåã®å¥åº·èšºæã®çµæããŸãšããŠèŠæ¯ã¹ãããã«ããŠããŸããäžå¹Žã ãã ãšãåºæºå€å ã ãã倧äžå€«ãã§çµãã£ãŠããŸããŸããã䞊ã¹ãŠã¿ããšå°ããã€å€åããŠããé ç®ã«æ°ã¥ããŸããæ©ãã«ç掻ãèŠçŽããã£ããã«ãªããŸãããåãããšãããŠããæ¹ã¯ããŸããã
çè·åž«ãããŠããŸãã å¥åº·èšºæã®çµæãåãåã£ãŠããã©ã®æ°å€ãæ°ã«ããã°ãããåãããªãããšãã声ãããèããŸããç§èªèº«ã¯ãå»å¹Žãšæ¯ã¹ãŠã©ãå€åãããããšãããå€åããèŠãããã«ããŠããŸãã1幎ã§å€§ããåããé ç®ãããã°ãçæŽ»ãæ¯ãè¿ããã£ããã«ããŠããŸãã çããã¯çµæã®ã©ããèŠãŠããŸããã
æ é€ã®å匷ãããŠããŸãã è žå ç°å¢ã®è©±é¡ãå¢ããŠããã®ã§ãèªåã§ãçºé µé£åãæ¯æ¥å°ããã€åãããã«ããŠããŸããçŽè±ããšãŒã°ã«ããå³åæ±ããããç¶ããããã§ãã åçã«äœããå€ãã£ããšããããããéããå®å®ããããªããšããçšåºŠã®å®æã§ãããç¡çãªãç¶ããããŠããã®ãäžçªã ãšæã£ãŠããŸããçããã®ç¿æ £ãç¥ãããã§ãã
Natureã2æã«å ±ããéããæ¥æ¬ã§éçºäžã®å¹¹çŽ°èæ²»çè¬ãæ£åŒæ¿èªã«åããæçµæ®µéã«å ¥ã£ãŠããŸããæ¡ä»¶ä»ãæ¿èªããæ£åŒæ¿èªãžã®ç§»è¡ãšããŠãåçå»çã®å®çšåã«ãããæŽå²çãªãã€ã«ã¹ããŒã³ãšãªããŸãã èæ¯ïŒ ã»æ¥æ¬ã®åçå»çç補åã®æ¡ä»¶ã»æéä»ãæ¿èªå¶åºŠïŒ2014幎æœè¡ïŒ ã»ãããŸã§7åç®ãæ¡ä»¶ä»ãæ¿èªãååŸ ã»æ£åŒæ¿èªã«è³ã£ãã®ã¯éå®çã§ãå¶åºŠã®æå¹æ§ãè°è«ãããŠãã ä»åã®æçŸ©ïŒ 1. æ¡ä»¶ä»ãæ¿èªâæ£åŒæ¿èªã®æåã¢ãã«ãç¢ºç« 2. é·æå®å šæ§ã»æå¹æ§ã®ãªã¢ã«ã¯ãŒã«ãããŒã¿èç© 3. ä¿éºåèŒã«åããå»ççµæžæ§ã®è©äŸ¡ äžççµæžãã©ãŒã©ã ïŒWEFïŒããåçå»çã¯ã°ããŒãã«çµæžã®åªå 課é¡ããšäœçœ®ã¥ããŠãããæ¥æ¬ã®å è¡äºäŸãäžççãªãã³ãããŒã¯ã«ãªãå¯èœæ§ããããŸãã äºé²å»åŠã®èŠç¹ããïŒ åçå»çã¯ãæ²»çãã®ã€ã¡ãŒãžã匷ãã§ããã倿§çŸæ£ã®æ©æä»å ¥ãšããŠäºé²çã«æŽ»çšã§ããå¯èœæ§ããçµç¹ã®å£åãäžå¯éã«ãªãåã«ä»å ¥ãããäºé²çåçå»çããšããã³ã³ã»ãããä»åŸæ³šç®ããããããããŸããã
Japan gives green light to first-of-their-kind stem cell therapies
Japan has approved two stem cell-based therapies for treating Parkinsons disease and heart failure in a world first.
www.medicalnewstoday.com
å é±Lancetã«æ²èŒãããå€§èŠæš¡ååãã³ããŒãç ç©¶ïŒn=502,536ã远跡æé12.4幎ïŒã®çµæãã·ã§ã¢ããŸãã äž»ãªç¥èŠïŒ ã»å°äžæµ·é£ã¹ã³ã¢äžäœ25%ïŒèº«äœæŽ»åã¬ã€ãã©ã€ã³éµå®çŸ€ â èªç¥çãªã¹ã¯40%äœäžïŒHR: 0.60, 95%CI: 0.53-0.68ïŒ ã»å°äžæµ·é£ã®ã¿ â 22%äœäž ã»éåã®ã¿ â 18%äœäž ã»äž¡æ¹çµã¿åããã广ã¯å ç®çã§ã¯ãªããçžä¹ç 泚ç®ãã¹ãã¯ãçžä¹å¹æãã®éšåã§ããé£äºãšéåãå¥ã ã«å®è·µãããããäž¡æ¹ãçµã¿åãããæ¹ãæããã«å¹æã倧ããã èšåºçŸå Žã§ã¯ããŸãã¯é£äºãããããŸãã¯æ©ãããšããããšæ®µéçã«æå°ããã¡ã§ãããã§ããã ãæ©æã«äž¡æ¹ã䞊è¡ããŠå§ããããšã®éèŠæ§ãè£ä»ãããã圢ã§ãã ç§ã®æ åœæ£è ããã«ãæ©éå ±æããããšæããŸãã
Mediterranean diet and physical activity in dementia prevention â The Lancet
A prospective cohort study of 502,536 participants showing synergistic effects of diet and exercise
www.thelancet.com
å¥åº·èšºæã®çµæãåå¿è åãã«ãŸãšããŸãããHbA1cãLDLã³ã¬ã¹ãããŒã«ãeGFRãªã©ã®åºæºå€ãšãèŠæ³šæã®æ°å€ã«ã€ããŠã䞻治å»ããæããŠããã£ãå®è·µçãªã¢ããã€ã¹ãå ±æããŸãã幎ã«äžåºŠã®å¥èšºãæå€§é掻çšããŸãããã
åšå® å€åã§éåäžè¶³ãæ·±å»ã ã£ãã®ã§ãèªå® ã«ãããžã ãäœããŸããããšã¬ãããããã³ãã«ãæžåããŒã®3ç¹ã»ããã§ååãæ¯æ¥30åã®éåã3ã¶æç¶ããçµæãåçž®æè¡å§ã145â128ã«æ¹åããªãããªã®å°éå®¶ãšããŠãèªä¿¡ãæã£ãŠããããããŸãã
ã¡ããã«ãã³ã飲ã¿å§ããŠ3ã¶æãHbA1cã7.2â6.5ã«æ¹åããŸãããé£äºç®¡çãšäœµçšããã®ã倧äºã ãšå®æãç¹ã«é£åŸã®è¡ç³å€ã¹ãã€ã¯ãæããããã®ã宿ããŠããŸããç®¡çæ é€å£«ããã®é£äºæå°ãšã®çµã¿åããã广çã§ãããåãè¬ãæçšããŠããæ¹ãæ å ±äº€æããŸãããïŒ